Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Dosage Forms × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

Dexamethasone 108 Cyclophosphamide 52 pomalidomide 51 Bortezomib 40 fludarabine phosphate 33 Lenalidomide 33 Peripheral Blood Stem Cell Transplantation 28 carfilzomib 26 Mycophenolic Acid 25 Calcium Dobesilate 24 daratumumab 23 Cyclosporine 22 Busulfan 21 Antilymphocyte Serum 20 Tacrolimus 19 Whole-Body Irradiation 18 Melphalan 17 Radiotherapy 15 Filgrastim 15 Methotrexate 14 fludarabine 12 Methylprednisolone 12 elotuzumab 11 Cord Blood Stem Cell Transplantation 11 selinexor 9 ixazomib 9 Etoposide 8 Thalidomide 7 Prednisone 7 Panobinostat 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡